spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  PONV 

 HSMN NewsFeed - 25 Sep 2024
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF(R) Vial Access Needle ("VAN")
Devices Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 4 Jan 2018
Acacia Pharma Announces FDA Acceptance of NDA Filing For BAREMSIS(R) for the Management of Post-operative Nausea & Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Aug 2016
Acacia Pharma Announces Positive Results From a Pivotal Phase 3 Trial of BAREMSIS(TM) for the Treatment of Post-Operative Nausea & Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 29 Jul 2015
Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 8 May 2014
Charleston Laboratories, Inc., Bolsters Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jun 2011
TESARO Announces $101 Million Series B Financing for Advancement and Expansion of Oncology Product Portfolio
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 9 Sep 2009
New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2009
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2009
Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Mar 2008
FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2007
MGI PHARMA and HELSINN Announce Submission of Supplemental New Drug Application for Aloxi(R) Injection in Post-Operative Nausea and Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2007
MGI PHARMA and HELSINN HEALTHCARE SA Announce Patent Extension for Aloxi(R) Injection
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2006
MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi(R) (Palonosetron Hydrochloride) Injection for the Prevention of Post Operative Nausea & Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 11 Jul 2006
FDA Approves EMEND(R) (aprepitant), Merck's Antiemetic Therapy, for the Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
PONV
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!